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in 100% cases. All patients were treated with crystalloids, sorbents,
croseltamivir and antibiotics.
Conclusion:Weassume that diarrhea in patientswith inﬂuenza
B in majority of cases associated with the development or worsen-
ing of common immunosuppression and dysbiotic changes in the
intestine. It is often associated with bacterial complications.
http://dx.doi.org/10.1016/j.ijid.2016.02.959
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Background: One of the key position in hemostasis belongs to
surface platelet receptors (SPR) - glycoproteins (GP) Ia/IIa, Ib/IX and
IIb/IIIa. Antibodies to SPR can lead to development of thrombocy-
topenia in patients with chronic HCV-infection. However the role
of different types of antibodies in this process is unknown.
Aim: to estimate the role of different types of antibodies to sur-
face platelet receptors in HCV-associated thrombocytopenia.
Methods & Materials: he detection GP Ia/IIa, Ib/IX and IIb/IIIa
was made by the ELISA technique in patients with HCV and
thrombocytopenia (group 1, n=29), HCV without thrombocytope-
nia (group 2, n=28) and healthy people (group 3, n=32). All patients
were untreated with interferon and ribavirin.
Results: Anti-GP Ia/IIa were detected in 44,8±9,2% in 1th group,
3,6 ± 3,5% in 2th group, 12,5±5,8% in 3th group, p1-2<0,01, p1-
3<0,05. Anti-GP Ib/IX were indicated in 55,2±9,2% in 1th group,
10,7±5,8% in 2th group, and 28,1±7,9% in 3th group, p1-2<0,01,
p1-3<0,05. Anti- GP IIb/IIIa were recorded in the same groups in
24,1±8,0%, 17,8±7,3% and 25±7,6% accordingly without any statis-
tical difference (Fig. 1).
Mean optical density (MOD) of anti-GPIa/IIa in 1th group also
was more signiﬁcant than in 2th and 3th group (0,331±0,035,
0,208±0,015 and 0,217±0,012 accordingly, p1-2<0,01, p1-3<0,01).
More high level of anti- GPIb/IX MOD was also recorded in 1th
group than in 2th group (0,280±0,025 and 0,215±0,010 p<0,05),
no statistical evidence was found between 3th group and patients
in 1th and 2th groups. Investigation of anti-GP IIb/IIIa MOD also
Fig. 1. Frequencyof detection the antibodies toplatelet antigensGP IIb/IIIa, GP Ib/IX,
GPIa/IIa in different groups.
Fig. 2. Relative concentration of anti-platelet in different groups.
did not ﬁnd any statistical difference between patients with HCV-
infected patients (both groups) and healthy people (Fig. 2)
Conclusion: High frequency of revealing and signiﬁcant level
of MOD of anti-GP Ia/IIa и Ib/IX in HCV-infected patients with
thrombocytopenia demonstrated the evidence of damage in the
ﬁrst stages of primary hemostasis: adhesion of platelets to colla-
genwith support ofGP Ia/IIa and stabilizationof this aggregatewith
support of collagen-binding activity of GP Ib/IX (factor Von Wille-
brand) as well as more high risk of destruction platelets binding
with anti-GP Ia/IIa and anti- GP Ib/IX in spleen. Detection of anti-
GP Ia/IIa и Ib/IX can serve as prognostication criteria for developing
thrombocytopenia in patients with chronic HCV-infection.
http://dx.doi.org/10.1016/j.ijid.2016.02.960
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Indian experience with use of sofusbuvir for
treatment of hepatitis C virus infection:
Preliminary data from southern India
K. Radhakrishnan ∗, A. Karunakaran, S. Jindal, A.
Raghavendran, A. Goel, S. Kattiparambil
Gangadharan, U.G. Zachariah, C.E. Eapen, P.
Abraham
Christian Medical College, Vellore, India
Background: Hepatitis C virus (HCV) infection is a major health
problem worldwide. India has a burden of over 10 million HCV
chronic carriers. The previous standard of care for HCV was pegy-
lated IFN (Peg IFN) and ribavirin (RBV). The new direct acting
antivirals that are now available promise sustained virological
response, tolerability and higher cure rates. This study aims to
look at the response to sofosbuvir (SOF) (an NS5B nucleotide ana-
log) in combination with RBV with/ without Peg IFN among Indian
patients.
Methods & Materials: Plasma from 44 patients (including 5
post transplant) was obtained from those who were treated with
SOF and RBV ± PegIFN. RNA extraction and ampliﬁcation was done
using real time PCR. HCV genotypes were ascertained using the
NS5B region based sequencing. Samples were tested for RNA nega-
tivity, onemonthafter treatment initiation (RVR), and3 to6months
later.
Results: Thirty eight of 44 patients were genotyped. Genotype
distribution was 7(18.4%) for type 1, 28(73.7%)for type3, 3(9%) for
type 4 respectively. Patients with 1, 3 & 4 genotypes on additional
Peg IFN was 4(10.5%), 5(14.7%) & 1(2.94%) and without Peg IFN was
3(7.9%), 23(60.5%)&2(5.9%). RVR for all patientswas100%andat≥3
month follow up, there was 100% response to SOF based therapy.
RVR for the 5 post transplant patients was 100%.
